Seminars in Hematology
Volume 47, Issue 3 , Pages 249-257 , July 2010

Clinical Findings With the First Generation of Thrombopoietic Agents

  • Saroj Vadhan-Raj

      Affiliations

    • Corresponding Author InformationAddress correspondence to Saroj Vadhan-Raj, MD, Section of Cytokines and Supportive Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030

References 

  1. Kaushansky K. The thrombocytopenia of cancer (Prospects for effective cytokine therapy). Hematol Oncol Clin North Am. 1996;10:431–455
  2. Prow D, Vadhan-Raj S. Thrombopoietin: biology and potential clinical applications. Oncology (Huntingt). 1998;12:1597–1604
  3. Elting LS, Rubenstein EB, Martin CG, et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol. 2001;19:1137–1146
  4. Benjamin RJ, Anderson KC. What is the proper threshold for platelet transfusion in patients with chemotherapy-induced thrombocytopenia?. Crit Rev Oncol Hematol. 2002;42:163–171
  5. Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1519–1538
  6. Vadhan-Raj S, Cohen V, Bueso-Ramos C. Thrombopoietic growth factors and cytokines. Curr Hematol Rep. 2005;4:137–144
  7. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood. 2002;100:3457–3469
  8. Tepler I, Elias L, Smith JW, et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood. 1996;87:3607–3614
  9. Basser RL, Rasko JE, Clarke K, et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet. 1996;348:1279–1281
  10. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production in a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med. 1997;126:673–681
  11. Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl M Med. 1997;336:404–409
  12. Basser RL, Rasko JE, Clarke K, et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human magakaryocyte growth and development factors with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood. 1997;89:3118–3128
  13. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med. 2000;132:364–368
  14. Murray LJ, Luens KM, Estrada MF, et al. Thrombopoietin mobilizes CD34+ cell subsets into peripheral blood and expands multilineage progenitors in bone marrow of cancer patients with normal hematopoiesis. Exp Hematol. 1998;26:207–216
  15. Basser RL, Underhill C, Davis I, et al. Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer. J Clin Oncol. 2000;18:2852–2861
  16. Vadhan-Raj S, Patel S, Broxmeyer H, et al. Schedule-dependent reduction in thrombocytopenia by recombinant human thrombopoietin (rhTPO) in patients with sarcoma receiving high dose chemotherapy (CT) with adriamycin (A) and ifosfamide (I) [abstract]. J Clin Oncol. 1999;18:52a
  17. Crawford J, Glaspy J, Belani C, et al. A randomized, placebo-controlled, blinded, dose scheduling trial of pegylated recombinant human megakaryocyte growth and development factor (PEG-HUMGDF) with filgrastim support in non small cell lung cancer (NSCLC) patients treated with paclitaxel and carboplatin during multiple cycles of chemotherapy [abstract]. Proc Am Soc Clin Oncol. 1998;17:73a
  18. Vadhan-Raj S, Patel S, Bueso-Ramos C, et al. Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. J Clin Oncol. 2003;21:3158–3167
  19. Moskowitz CH, Hamlin PA, Gabrilove J, et al. Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma. Ann Oncol. 2007;18:1842–1850
  20. Angiolillo AL, Davenport V, Bonilla MA, et al. A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factors in children receiving ifosfamide, charboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience. Clin Cancer Res. 2005;11:2644–2650
  21. Archimbaud E, Ottoman OG, Yin JA, et al. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factors (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de-novo acute myeloid leukemia. Blood. 1999;94:3694–3701
  22. Schiffer CA, Miller K, Larson RA, et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood. 2000;95:2530–2535
  23. Cripe L, Neuberg D, Tallman M, et al. A pilot study of recombinant human thrombopoietin (rh-TPO) and GM-CSF following induction therapy in patients older than 55 years with acute myeloid leukemia (AML) [abstract]. Blood. 1998;92:616a
  24. Geissler K, Yin JA, Ganser A, et al. Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for the novo acute myeloid leukemia—a randomized, placebo-controlled, double-blind safety and efficacy study. Ann Hematol. 2003;95:2530–2535
  25. Bolwell B, Vredenburgh J, Overmoyer B, et al. Phase I study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation. Bone Marrow Transplant. 2000;26:141–145
  26. Wolf SN, Herzig R, Lynch J, et al. Recombinant human thrombopoietin (rhTPO) after autologous bone marrow transplantation: a phase I pharmacokinetic and pharmacodynamic study. Bone Marrow Transplant. 2001;27:261–268
  27. Schuster MW, Beveridge R, Fre-Lahr D, et al. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation. Exp Hematol. 2002;30:1044–1050
  28. Nash RA, Kurzrock R, DiPersio J, et al. A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2000;6:25–34
  29. Somlo G, Sniecinski I, ter Veer A, et al. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy. Blood. 1999;93:2798–2806
  30. Linker C, Anderlini P, Herzig R, et al. A randomized, placebo-controlled, phase II trial of recombinant human thrombopoietin (rhTPO) in subjects undergoing high dose chemotherapy (HDC and PBPC transplant [abstract]. Blood. 1998;92:682a
  31. Linker C. Thrombopoietin in the treatment of acute myeloid leukemia and in stem-cell transplantation. Semin Hematol. 2000;37:35–40
  32. Kuter DJ, Goodnough LT, Romo J, et al. Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood. 2001;98:1339–1345
  33. Goodnough LT, Kuter DJ, McCullough J, et al. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. Blood. 2001;98:1346–1351
  34. Vadhan-Raj S, Kavanagh JJ, Freedman RS, et al. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomized cross-over study. Lancet. 220;359:2145-52.
  35. Liu Yin JA, Adams JA, Brereton ML, et al. Megakaryopoiesis in vitro in myelodysplastic syndromes and acute myeloid leukaemia: effect of pegylated recombinant human megakaryocyte growth and development factor in combination with other growth factors. Br J Haematol. 2000;108:743–746
  36. Fontenay-Roupie M, Dupont JM, Picard F, et al. Analysis of megakaryocyte growth and development factor (thrombopoietin) effects on blast cell and megakaryocyte growth in myelodysplasia. Leuk Res. 1998;22;:527–535
  37. Komatsu N, Okamoto T, Yoshida T, et al. Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) increased platelet counts (plt) in patients with aplastic anemia (AA) and myelodysplastic syndrome (MDS) [abstract]. Blood. 2000;96:296a
  38. Vadhan-Raj S, Broxmeyer HE, Spitzer G, et al. Stimulation of nonclonal hematopoiesis and suppression of the neoplastic clone after treatment with recombinant human granulocyte-macrophage colony-stimulating factor in a patient with therapy-related myelodysplastic syndrome. Blood. 1989;74:1491–1498
  39. Nomura S, Dan K, Hotta T, Fujimura K, Ikeda Y. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood. 2002;68:210–214
  40. Rice L, Nichol JL, McMillan R, Roskos LK, Bacile M. Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy. Am J Hematol. 2001;68:210–214
  41. Harker LA, Marzec UM, Novembre F, et al. Treatment of thrombocytopenia in chimpanzees infected with human immunodeficiency virus by pegylated recombinanat human megakaryocyte growth and development factor. Blood. 1998;91:4427–4433
  42. Harker LA, Carter RA, Marzec UM, et al. Correction of thrombocytopenia and ineffective platelet production in patients infected with human immunodeficiency virus (HIV) by PEG-rHuMGDF therapy [abstract]. Blood. 1998;92(Suppl 1):707a
  43. Douglas VK, Tallman MS, Cripe LD, Peterson LC. Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders. Am J Clin Pathol. 2002;117:844–850
  44. Vigon I, Dreyfus F, Melle J, et al. Expression of the c-mpl proto-oncogene in human hematologic malignancies. Blood. 82;877-83.
  45. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98:3241–3248
  46. Yang C, Xia Y, Li J, Kuter DJ. The appearance of anti-thrombopoietin antibody and circulating thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor [abstract]. Blood. 1999;94:681a
  47. Basser RL, O'Flaherty E, Green M, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood. 2002;99:2599–2602
  48. Vadhan-Raj S, Abboud C, Niesvizky R, et al. Thrombocytopenia associated with administration of a C-MPL receptor agonist. Am Soc Clin Oncol. 2000;53a:Abstract 206
  49. Kuter DJ. New thrombopoietic growth factors. Blood. 2007;109:4607–4616
  50. Vadhan-Raj S, Trent J, Araujo DM, Patel S, Zhou X, Benjamin RS. Evaluation of AMG 351 in chemotherapy-induced thrombocytopenia (CIT): results of a phase I/II study. Am Soc Clin Oncol. 2009;abstract e20616
  51. Natale R, Charu V, Schutte W, et al. Safety of romiplostim for treatment of chemotherapy-induced thrombocytopenia (CIT) in patients with advanced non-small cell lung cancer (NSCLC). 2009;ECCO-ESMO Congress; Berlin
  52. Fanale M, Stiff P, Nooman K, McCoy J, Rutstein M, Moskowitz C. Safety of romiplostim for treatment of severe chemotherapy induced thrombocytopenia (CIT) in patients with lymphoma receiving multicycle chemotherapy; results from an open-label dose-and schedule finding study. 2009;(NSCLC). ECCO-ESMO Congress; Berlin

PII: S0037-1963(10)00045-4

doi: 10.1053/j.seminhematol.2010.03.004

Seminars in Hematology
Volume 47, Issue 3 , Pages 249-257 , July 2010

Article Tools

* Image Usage & Resolution